Value Bridge — BETH ISRAEL DEACONESS MEDICAL CENTER
Current $-84M → Target $-47M (+$37.0M)
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$-83.7M
Current EBITDA
$-46.7M
Target EBITDA
+$37.0M
Total Uplift
7
Value Levers
EBITDA Bridge — 7 Lever Model
Each lever shows gross impact, probability of achievement, and probability-weighted value.
Denial Rate Reduction
$0.0M
AR Acceleration
$0.0M
Coding Accuracy Uplift
$8.4M
Payer Mix Optimization
$20.1M
Cost to Collect Reduction
$6.7M
Clean Claim Improvement
$5.0M
Volume & Rate Growth
$33.5M
What This Means
The 7-lever model projects a 0% EBITDA uplift from $-84M to $-47M. The highest-impact lever is Volume & Rate Growth at $13.4M probability-weighted.
IC talking point: "We see $37M in annual EBITDA improvement, primarily from volume & rate growth. At an 11x multiple, this represents $407M in equity value creation."